CRSP Stock: Price, Earnings History and SEC Filings
CRISPR Therapeutics AG (CRSP) last traded at $51.42, down 5.23% on the latest session and down 7.0% over the past month. In its most recent reported quarter (Jun 2026) earnings per share were $-0.94 against an analyst estimate of $-1.10, a beat of 14.5%.
$51.42 -5.23%
1 month-7.05%
52-week high$64.74
52-week low$44.12
Volume1.17M
ExchangeNasdaqGM
Price data from Yahoo Finance, as of Oct 30, 2026. May be delayed.
CRSP earnings history
| Quarter | Reported | EPS | Estimate | Surprise |
|---|---|---|---|---|
| Jun 2026 | Aug 3, 2026 | $-0.94 | $-1.10 | +14.55% |
| Mar 2026 | May 4, 2026 | $-1.28 | $-1.14 | -12.28% |
| Dec 2025 | Feb 12, 2026 | $-1.37 | $-1.15 | -19.13% |
| Sep 2025 | Nov 10, 2025 | $-1.17 | $-1.32 | +11.36% |
CRSP beat the analyst EPS estimate in 2 of its last 4 reported quarters. Source: Nasdaq.
Latest SEC filings for CRSP
SEC filing data is not available right now. You can search for CRSP on SEC EDGAR.
CRSP news
- Here's Why CRISPR Therapeutics AG (CRSP) Fell More Than Broader MarketOct 30, 2026 · finance.yahoo.com
- Fidelity’s Health Care ETF Holds the Biotechs XLV Skips. Retirees Should Know the DifferenceOct 30, 2026 · 247wallst.com
- 3 Promising Genomics Stocks to Add to Your Portfolio NowOct 30, 2026 · finance.yahoo.com
- Vertex Gears Up to Report Q3 Earnings: Is a Beat in the Cards?Oct 27, 2026 · finance.yahoo.com
- Learn Why The Bull Case For CRISPR Therapeutics Stock Could Change Following CFO ChangeOct 25, 2026 · finance.yahoo.com
- CRISPR Therapeutics (CRSP) Promotes Andrew Silver To CFO As Raju Prasad ResignsOct 25, 2026 · finance.yahoo.com
- Forget Casgevy: CRISPR Therapeutics' Heart-Disease Data Could Matter MoreOct 24, 2026 · fool.com
- CRISPR Therapeutics AG (CRSP) Dips More Than Broader Market: What You Should KnowOct 23, 2026 · finance.yahoo.com
About CRISPR Therapeutics AG
CRISPR Therapeutics AG (CRSP) is a US-listed public company on Nasdaq.